Stuttgart - Delayed Quote EUR

Arcadia Biosciences Inc (17D.SG)

Compare
4.1800
-0.2000
(-4.57%)
At close: 9:32:18 PM GMT+1
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
5,482
5,330
7,418
6,780
8,034
Cost of Revenue
3,440
3,300
6,101
8,708
5,199
Gross Profit
2,042
2,030
1,317
-1,928
2,835
Operating Expense
16,331
15,895
16,545
26,827
24,427
Operating Income
-14,289
-13,865
-15,228
-28,755
-21,592
Net Non Operating Interest Income Expense
585
695
289
-20
-47
Other Income Expense
5,143
13
4,125
12,643
15,489
Pretax Income
-8,561
-13,157
-10,814
-16,132
-6,150
Tax Provision
7
8
14
2
-124
Net Income Common Stockholders
-5,827
-13,981
-15,376
-14,660
-4,655
Diluted NI Available to Com Stockholders
-5,827
-13,981
-15,376
-14,660
-4,655
Basic EPS
-4.17
-11.30
-25.65
-27.60
-18.80
Diluted EPS
-4.17
-11.30
-25.65
-27.60
-18.80
Basic Average Shares
1,362.4840
1,236.9340
599.3890
532.0150
248.9750
Diluted Average Shares
1,362.4840
1,236.9340
599.3890
532.0150
248.9750
Total Operating Income as Reported
-10,398
-13,938
-14,007
-35,526
-12,778
Total Expenses
19,771
19,195
22,646
35,535
29,626
Net Income from Continuing & Discontinued Operation
-5,827
-13,981
-15,376
-14,660
-4,655
Normalized Income
-12,488.7700
-13,554.6050
-15,017.5700
-17,067.5400
-19,123.7690
Interest Income
585
695
289
--
--
Interest Expense
--
--
--
20
47
Net Interest Income
585
695
289
-20
-47
EBIT
-14,289
-13,865
-15,228
-28,755
-6,103
EBITDA
-14,137
-13,578
-14,749
-27,710
-5,441
Reconciled Cost of Revenue
3,440
3,300
6,101
8,708
5,199
Reconciled Depreciation
152
287
479
1,045
662
Net Income from Continuing Operation Net Minority Interest
-8,568
-13,160
-10,592
-14,660
-4,655
Total Unusual Items Excluding Goodwill
4,963
395
4,430
3,298
14,749
Total Unusual Items
4,963
395
4,430
3,298
14,749
Normalized EBITDA
-19,100
-13,973
-19,179
-31,008
-20,190
Tax Rate for Calcs
0.0002
0
0
0.0003
0
Tax Effect of Unusual Items
1,042.2300
0.3950
4.4300
890.4600
280.2310
12/31/2020 - 3/16/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade